Skip to main content

Table 1 Baseline characteristics

From: Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study

Clinical characteristicsGeneral population (n = 4,324,545)Cancer population
(n = 316,040)
Male sex2,176,883 (50.3)153,258 (48.5)
Median (SD*) age (years)44.8 (18.0)67.0 (13.3)
Comorbidity:
 Stroke63,619 (1.5)19,589 (6.2)
 Ischemic heart disease64,596 (1.5)17,297 (5.5)
 Heart failure22,271 (0.5)6226 (2.0)
 Hypertension179,184 (4.1)111,157 (35.2)
 Vascular disease83,119 (1.9)25,590 (8.1)
 Previous bleeding27,104 (0.6)36,996 (11.7)
 Chronic obstructive pulmonary disease19,639 (0.5)19,127 (6.1)
 Chronic kidney disease36,595 (0.9)8962 (2.8)
 Misuse of alcohol or psychoactive substance73,056 (1.7)17,533 (5.6)
 Hyperthyroid disease29,945 (0.7)9704 (3.1)
 Previous embolus81,350 (1.9)26,708 (8.5)
 Liver disease27,104 (0.6)9395 (3.0)
Pharmacotherapy
 Calcium channel blocker154,619 (3.6)43,591 (13.8)
 ACE† inhibitors173,182 (4.0)67,737 (21.4)
 Beta blockers158,308 (3.7)42,629 (13.5)
 Spironolactone18,023 (0.4)9132 (2.9)
 Loop diuretic118,914 (2.8)35,159 (11.1)
 Thiazide diuretic168,222 (3.9)43,289 (13.7)
 Aspirin175,178 (4.1)60,598 (19.2)
 Clopidogrel1444 (0.03)4488 (1.4)
 Warfarin1558 (0.5)7376 (2.3)
 Digoxin41,430 (1.0)6852 (2.2)
 Cholesterol-lowering drug62,599 (1. 5)50,301 (15.9)
 Glucose-lowering medication8791 (2.9)22,979 (7.2)
 Inhalation medication222,169 (5.1)40,355 (12.8)
  1. Baseline characteristics for the general population and the cancer population. Values are numbers (percentages) unless stated otherwise
  2. *SD = standard deviation, †ACE = angiotensin converting enzyme